Polaryx Therapeutics (NASDAQ:PLYX) CEO Buys $360,003.71 in Stock

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) CEO Alex Keun Mo Yang purchased 88,453 shares of Polaryx Therapeutics stock in a transaction that occurred on Wednesday, May 27th. The stock was acquired at an average price of $4.07 per share, for a total transaction of $360,003.71. Following the transaction, the chief executive officer directly owned 24,233,249 shares of the company’s stock, valued at $98,629,323.43. The trade was a 0.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Polaryx Therapeutics Stock Performance

PLYX traded up $0.54 during trading hours on Thursday, hitting $3.05. The company’s stock had a trading volume of 853,993 shares, compared to its average volume of 1,495,093. The firm has a 50-day moving average of $5.06. Polaryx Therapeutics, Inc. has a 12 month low of $2.07 and a 12 month high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PLYX. Maxim Group began coverage on shares of Polaryx Therapeutics in a research report on Friday, February 27th. They issued a “buy” rating and a $10.00 price target on the stock. Weiss Ratings began coverage on shares of Polaryx Therapeutics in a research report on Friday, April 24th. They set a “sell (e-)” rating on the stock. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.